Amryt Pharma plc
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
4/10
|
39.35 | 61.47 | -35.99% | 5.69 | +591.81% |
| P/S |
|
3.85 | 33.58 | -88.55% |
|
|
| P/BV |
|
2.85 | 4.79 | -40.61% |
|
|
| P/FCF |
|
7.91 | 60.06 | -86.83% |
|
|
| Ev/Ebitda |
|
16.25 | -17.26 | -194.16% |
|
|
| Ev/S |
|
4.39 | 22.49 | -80.46% |
|
|
| Ev/FCF |
|
10.06 | 67.63 | -85.13% |
|
|
| E/P |
|
-0.0241 | 0.0168 | -243.09% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
8/10
|
26.99 | -12.31 | -319.36% | 10.28 | +162.6% |
| ROE |
|
-6.1 | 9.39 | -164.95% |
|
|
| ROA |
|
-2.66 | 0.1519 | -1847.68% |
|
|
| ROIC |
|
4.77 | 7.63 | -37.52% |
|
|
| ROS |
|
-8.34 | -25.64 | -67.47% |
|
|
| ROCE |
|
1.07 | 14.76 | -92.75% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
4/10
|
3.29 | -3.68 | -189.31% | 3.4 | -3.33% |
| Nеt Debt/Ebitda |
|
2 | -4.07 | -149.18% |
|
|
| Debt/Ratio |
|
0.2888 | 0.199 | 45.13% |
|
|
| Debt/Equity |
|
0.9482 | 1.67 | -43.05% |
|
|
| Debt/Net Income |
|
-10.63 | 10.34 | -202.82% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5399 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2331 | -100% |
|
|
| Average dividend growth |
|
0 | 1.07 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4916 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.32 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5399 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
319.1 | 76.2 | 318.77% | ||
| Growth impulse Ebitda in 5 years |
|
215.17 | 44.75 | 380.83% | ||
| Growth impulse Net Income in 5 years |
|
-98.79 | -15.36 | 543.16% | ||
| Growth impulse FCF in 5 years |
|
-802.73 | -9.39 | 8448.78% | ||
| Growth impulse EPS in 5 years |
|
-108.57 | -84.03 | 29.2% |
IP Score
3.87/10
